Status:
RECRUITING
CHASE Registry of Patients With Pulmonary Hypertension Receiving Targeted Therapy
Lead Sponsor:
Chinese Pulmonary Vascular Disease Research Group
Conditions:
Pulmonary Hypertension
Eligibility:
All Genders
18-85 years
Brief Summary
CHina Registry for the chAracteristics and Management strategieS of patiEnts With Pulmonary Hypertension Using Targeted Therapy (CHASE Study)
Detailed Description
The purpose of this study was to establish the clinical characteristics and treatment strategies of targeted pulmonary hypertension patients in China: a multicenter, prospective case registry (CHASE) ...
Eligibility Criteria
Inclusion
- Sign informed consent;
- Between the ages of 18 and 85;
- Clinical diagnosis of pulmonary hypertension, using or planning to use pulmonary hypertension targeted drugs (including any one or more of the following: prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase inhibitors, soluble guanylate cyclase agonists and prostacyclin receptor agonists).
Exclusion
- Have a history of mental illness or drug or poison addiction, and can not sign informed consent or can not cooperate with the experimental study;
- Patients with malignant tumor and other diseases and life expectancy of less than half a year;
- Short-term (less than 2 weeks) patients taking targeted drugs for pulmonary hypertension
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
5000 Patients enrolled
Trial Details
Trial ID
NCT06135909
Start Date
January 1 2020
End Date
December 31 2027
Last Update
January 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Respiratory and Pulmonary Vascular Diseases, Fuwai hospital, CAMS & PUMC
Beijing, China, 100037